Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug maker Amylin Pharmaceuticals
So what: Diabetes treatment Bydureon has been recommended for approval by Europe's Committee for Medicinal Products for Human Use. The drug is being developed with Alkermes
Now what: After being pummeled when Bydureon failed to meet primary endpoints in a study last month, this is certainly good news for shareholders. Considering the volatile nature of the stock and constant surprises one way or the other, it's still a risky proposition to buy on this news. I'm going to stick firmly on the sidelines, considering the stock has let investors down more than once before.
Interested in more info on Amylin Pharmaceuticals? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.